NAD+ nasal spray offers a needle-free route, while home injections involve a different administration process and set of practical responsibilities. Neither format can be declared equivalent from its ingredient name alone.
A useful comparison starts with the actual prescription and label. Claims about rapid brain delivery, superior absorption, or an immediate energy response need route-specific human evidence rather than an appealing explanation of the route.
Nasal NAD is needle-free, but that does not establish equivalent dosing or superior brain effects. Compare the exact prescription, evidence, support, and route-specific total.
The practical difference is real
A nasal preparation uses the nasal route; a subcutaneous preparation is administered under the skin. Avoiding needles may matter to a reader, but it does not establish that the nasal product is more effective or suitable.
Ask the clinician what the proposed route is intended to achieve and how the decision accounts for your circumstances. The route overview places both beside IV care without treating them as the same intervention.
Nose-to-brain language needs a matching study
A provider may discuss a plausible delivery pathway or cite research involving another substance, animals, or a different preparation. That does not automatically demonstrate a meaningful brain or memory benefit from the nasal prescription being sold.
Likewise, the NAD IV metabolome pilot cannot establish the effectiveness of either a nasal product or a home shot. Ask for the exact molecule, formulation, route, participant group, and clinical outcome in the supporting study.
Spray counts and injection volumes are not interchangeable
A nasal bottle may describe concentration and an amount per actuation, while a vial may describe concentration and total volume. Device characteristics and product instructions are part of the prescription.
Do not calculate a route switch by matching sprays to syringe markings or borrowing another brand’s instructions. The label and storage guide explains why clarification should come from the dispensing pharmacy and prescribing team.
Compare each route’s actual price
AgelessRx separates monthly and one-time nasal options, and Shed offers several NAD formats under a general starting-price headline. CoreAge also advertises nasal and injection options. These are reasons to request a route-specific quote, not to assume every format costs the same.
The nasal shortlist and CoreAge versus Shed comparison keep the selected format visible. Ask about the full supply period and renewal as well as the entry price.
Portability still requires a care and storage plan
A small nasal bottle may be convenient to carry, but it still needs the preparation’s storage instructions and a plan for follow-up. An injection kit adds other handling requirements. Neither route creates automatic treatment eligibility when you travel.
Use the travel options guide to organize those questions. Compounded prescriptions are not FDA-approved, and convenience should remain separate from clinical evidence and product-quality verification.
Sources & reading notes
Editorial source review updated September 19, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- AgelessRx: NAD+ Nasal Spray Provider lists $125/month subscription and $140 one-time purchase; customer check-ins are uncontrolled reports. Checked September 18, 2026.
- Shed: NAD+ routes and prices Provider lists nasal spray from $144/month and injections or oral tablets from $169/month. Checked September 18, 2026.
- CoreAge Rx: NAD+ Nasal Provider description of a different administration route.
- Grant et al. (2019): NAD+ infusion metabolome pilot Small human IV study; metabolic observations do not prove longevity or everyday benefits.
- FDA: compounding questions and answers Explains that compounded drugs are not FDA-approved.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.